Article: Mitoxantrone

Mitoxantrone
Systematic (IUPAC) name
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino) ethylamino]-anthracene-9,10-dione
Identifiers
CAS number	65271-80-9
ATC code	L01DB07
PubChem	4212
DrugBank	APRD00371
Chemical data
Formula	C22H28N4O6
Mol. weight	444.481 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	78%
Metabolism	Hepatic (CYP2E1)
Half life	75 hours
Excretion	Urinary
Therapeutic considerations
Pregnancy cat.	D (United States)
Legal status	Prescription Only
Routes	Exclusively intravenous

Mitoxantrone belongs to the general group of medicines known as antineoplastics, specifically the anthracycline class.

It is used to treat some kinds of cancer, including acute myelogenous leukemia. It is also used to treat some forms of multiple sclerosis (MS). This medicine will not cure MS, but may extend the time between relapses.

Mitoxantrone seems to interfere with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by mitoxantrone, other effects will also occur. Some of these may be serious. Other effects, like hair loss, may not be serious but may cause concern. Some effects may not occur for months or years after the medicine is used.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.